Literature DB >> 29869063

Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study.

Ying Wang1, Zhihong Shi2, Nan Zhang3, Li Cai1, Yansheng Li1, Hailei Yang1, Shaobo Yao1, Xiling Xing1, Yong Ji2, Shuo Gao4.   

Abstract

PURPOSE: To identify the most vulnerable network among typical and three variants of Alzheimer's disease (AD) and to link amyloid-β (Aβ) deposition and downstream network dysfunction. PROCEDURES: In this study, 38 typical AD, 11 frontal variants, 8 logopenic variants, 6 posterior variants, and 20 normal controls were enrolled. 2-(4'-[11C] Methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB) and 2-deoxy-2-[18]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) imaging were performed. Voxel-wise statistical analysis was used for [18F]FDG analysis, whereas two-sample t test was performed between each AD group and control group. Moreover, the goodness of fit (GOF) of t-maps with brain functional network templates was assessed, and the most vulnerable network in each phenotypic of AD was chosen as volume of interests (VOIs). [11C]PIB binding potential (BPND) of VOIs were generated by using PMOD software. In addition, statistical analysis of BPND among four types of AD in each specific network was calculated by SPSS software.
RESULTS: The hypometabolism patterns indicated that in typical and frontal variants of AD, the most vulnerable network was the left executive control network (GOF score = 4.3, 5.0). For the logopenic variant, the highest GOF score (1.9) belonged to the auditory network. For the posterior variant, the higher visual network was the most vulnerable (GOF score = 6.0). The [11C]PIB BPND showed that there were no significant differences (p > 0.05) among AD groups within the specific networks.
CONCLUSION: The phenotypic diversity of AD correlates with specific functional network failure; however, Aβ plaques do not associate with specific network vulnerability.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β; Positron-emission tomography; [11C]PIB; [18F]FDG

Mesh:

Substances:

Year:  2019        PMID: 29869063     DOI: 10.1007/s11307-018-1219-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  34 in total

Review 1.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

2.  Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.

Authors:  Randy L Buckner; Jorge Sepulcre; Tanveer Talukdar; Fenna M Krienen; Hesheng Liu; Trey Hedden; Jessica R Andrews-Hanna; Reisa A Sperling; Keith A Johnson
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 3.  Functional network disruption in the degenerative dementias.

Authors:  Michela Pievani; Willem de Haan; Tao Wu; William W Seeley; Giovanni B Frisoni
Journal:  Lancet Neurol       Date:  2011-07-21       Impact factor: 44.182

4.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Authors:  S Minoshima; B Giordani; S Berent; K A Frey; N L Foster; D E Kuhl
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

5.  A network diffusion model of disease progression in dementia.

Authors:  Ashish Raj; Amy Kuceyeski; Michael Weiner
Journal:  Neuron       Date:  2012-03-21       Impact factor: 17.173

6.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

7.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

8.  Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.

Authors:  Juan Zhou; Michael D Greicius; Efstathios D Gennatas; Matthew E Growdon; Jung Y Jang; Gil D Rabinovici; Joel H Kramer; Michael Weiner; Bruce L Miller; William W Seeley
Journal:  Brain       Date:  2010-04-21       Impact factor: 13.501

9.  Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.

Authors:  M H Rosenbloom; A Alkalay; N Agarwal; S L Baker; J P O'Neil; M Janabi; I V Yen; M Growdon; J Jang; C Madison; E C Mormino; H J Rosen; M L Gorno-Tempini; M W Weiner; B L Miller; W J Jagust; G D Rabinovici
Journal:  Neurology       Date:  2011-04-27       Impact factor: 9.910

10.  Metabolic brain networks in aging and preclinical Alzheimer's disease.

Authors:  Katelyn L Arnemann; Franziska Stöber; Sharada Narayan; Gil D Rabinovici; William J Jagust
Journal:  Neuroimage Clin       Date:  2017-12-28       Impact factor: 4.881

View more
  4 in total

1.  Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease.

Authors:  Ellen H Singleton; Yolande A L Pijnenburg; Carole H Sudre; Colin Groot; Elena Kochova; Frederik Barkhof; Renaud La Joie; Howard J Rosen; William W Seeley; Bruce Miller; M Jorge Cardoso; Janne Papma; Philip Scheltens; Gil D Rabinovici; Rik Ossenkoppele
Journal:  Alzheimers Res Ther       Date:  2020-11-14       Impact factor: 6.982

2.  Biodistribution and Dosimetry Evaluation for a Novel Tau Tracer [18F]-S16 in Healthy Volunteers and Its Application in Assessment of Tau Pathology in Alzheimer's Disease.

Authors:  Ying Wang; Li Cai; Kaixiang Zhou; Mengchao Cui; Shaobo Yao
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

3.  Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.

Authors:  Valeria Isella; Cinzia Crivellaro; Anna Formenti; Monica Musarra; Sara Pacella; Sabrina Morzenti; Francesca Ferri; Cristina Mapelli; Francesca Gallivanone; Luca Guerra; Ildebrando Appollonio; Carlo Ferrarese
Journal:  J Neurol       Date:  2022-03-26       Impact factor: 6.682

4.  Elevated matrix metalloproteinase-9 levels in neuronal extracellular vesicles in Alzheimer's disease.

Authors:  Dongmei Gu; Fang Liu; Meng Meng; Liling Zhang; Marc L Gordon; Ying Wang; Li Cai; Nan Zhang
Journal:  Ann Clin Transl Neurol       Date:  2020-08-13       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.